Wells Fargo maintains Nurix Therapeutics at Equal-Weight, lowers price target to $20 from $25
Wells Fargo kept Nurix Therapeutics at Equal-Weight but cut its price target to $20 from $25, a 20% reduction. This implies a 22.5% downside from the Nov 3 close of $25.82. Other recent analyst targets for the stock range from $32 to $36.
How this was made
The 30-second read
Why it matters
The downgrade signals a more cautious outlook, likely prompting short sellers and reducing buying interest.
Market read
Analyst target cuts are a common catalyst for price movement in small‑cap stocks; this note provides fresh guidance for traders.
What to watch
Potential upcoming clinical milestones or partnership announcements not covered in the note.
Background
Wells Fargo's research team regularly updates price targets for listed companies; this is the latest adjustment for Nurix.
Market effects
May weigh on other small‑cap biotech stocks as analysts reassess sector risk.
Limited to US biotech market.
Low
Counterpoint
If the target cut reflects temporary market overreaction, the stock could rebound on upcoming trial data.
Key entities
- AnalystWells Fargo
Equity research firm issuing the price target change.
- CompanyNurix Therapeutics
Biotech firm (NASDAQ: NURX) subject of the analyst downgrade.
